Neurovision Medical Products Receives Second Patent for Detection of Reversible Nerve Injury

NEUROVISION MEDICAL PRODUCTS, INC. announced that it has been granted United States Patent No. 10,517,493, making it the second patent related to the company’s nerve location platform, Nerveäna.

The Nerveäna system is designed to utilize the digital logic of NPI (Nerve Power Index) and gives surgeons the ability to collect and interpret data that detects nerve weakness before the onset of palsy during surgery. The technology allows surgeons to conveniently identify and avoid traction, stretching, or other insults that could lead to nerve damage. The ability to detect reversible nerve injury with the NPI algorithm can improve surgical outcomes for patients.

The NPI algorithm is an intuitive surgical tool that provides a real-time indication of the relative health and integrity of the nerve. A critical aspect of preventing irreversible nerve damage or vocal cord paralysis is the surgeon’s ability to identify and monitor at-risk motor nerves. With the unique algorithm, NMP has pioneered the use of data to expand the clinician’s awareness of nerve functionality intraoperatively. The NPI generates values corresponding to nerve strength within the dissecting process used to complete the surgery. Dr. James Lee Rea, CEO of NMP explains the distinct utilization of NPI:

“Unlike competitive platforms, the NPI requires no additional sensors and provides information by the same surgical instruments used in surgical maneuvers. A single NPI number, along with audio alerts, indicates the power of nerve and muscle response. The quality of conduction is audibly expressed by a two-tone system, with a higher-pitched tone occurring with an NPI >100, and a lower-pitched tone occurring with an NPI <100.”

NPI offers digital logic that can assist surgeons in their efforts to protect motor nerves and improve patient outcomes.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”